Share deal
Eric Campbell of the Institute for Health Policy at Massachusetts General Hospital in Boston applauds the new policy. "The two fundamental underpinnings of science are replication and peer review," he says. "If you hamstring one of these, you are hurting science."
Campbell believes that funding organizations have a responsibility to promote a culture of sharing. Two years ago, he surveyed some 1,200 academic geneticists and found that almost half of them had been denied requests for information or materials in the previous three years -as a result,28% of them were unable to replicate published findings (E. G. Campbell et al. J. Am. Med. Assoc. 287, 473-480; 2002) .
But the COGR is concerned about the way in which the NIH rules will be interpreted. When the changes were announced -fairly quietly in early May -the council wrote an open letter to the agency listing a number of concerns, including the lack of public consultation and a failure to deal with intellectual-property issues. Council president Katharina Phillips added that the NIH had not clarified what constitutes an acceptable sharing plan or the legal basis for the policy. Rather than insisting on detailed plans in grant applications, the COGR wants the NIH to accept a simple statement of intent to share materials. The NIH has promised to clarify its policy in a document soon, but this has not yet been published, and the COGR says that the agency should delay its October deadline until the concerns have been resolved. The NIH says that it remains committed to its timetable.
The rule change is in line with a report published last year by the US National Research Council, part of the National Academies, which argued that stronger community standards for sharing were needed. "The NIH are moving in the right direction," says Thomas Cech, president of the Howard Hughes Medical Institute in Chevy Chase, Maryland, and chairman of the committee that produced the sharing report.
Balancing act
Observers, however, point out that there is an inherent tension between the NIH, which seeks to maximize the impact of the research it supports, and the universities, which are entitled to patent and profit from inventions made with government funds. In some cases, such as that of frequently requested reagents, it may be in all parties' interests to license the materials to companies that supply them to other researchers. Under the new policy, NIH reviewers will then have to consider the terms under which materials will be available and determine whether the price is fair.
Licensing decisions are normally the responsibility of universities rather than individual researchers, and the NIH policy statement also warns that institutions will be held accountable for the sharing behaviour of their investigators. The risk of losing NIH funding represents a considerable threat, but proponents of the policy see this as a last resort. "We will use discretion," says Norka Ruiz Bravo, deputy director for extramural research at the agency."We don't want to use a hammer to swat flies." 
